Treace Medical Concepts Sees 6% Revenue Boost in Q2 2024
Treace Medical Concepts Inc. (TMCI) has reported a 6% increase in Q2 revenue, bringing the total to $44.5 million. This growth is primarily driven by an expanded surgeon base and the adoption of products like SpeedPlate and Adductoplasty. Despite facing competition and knockoff versions of its Lapiplasty product, the company has reaffirmed its full-year 2024 revenue guidance of $201 million to $211 million.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
